Total Trades
Politicians Trading
Last Traded
Price history
Congressional Trades
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
Total Trades
Politicians Trading
Last Traded
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
$125.59updated Jun 15, 2026
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Total Trades
11
Politicians Trading
6
Last Traded
Jan 27, 2026
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Josh GottheimerD | Feb 26, 2026 | Jan 27, 2026 | Buy | $1,001 - $15,000 | -10.91% |
| Val T. HoyleD | Oct 10, 2025 | Sep 23, 2025 | Sell | $1,001 - $15,000 | +9.78% |
| Marjorie Taylor GreeneR | Jun 18, 2025 | Jun 6, 2025 | Buy | $1,001 - $15,000 | +11.68% |
| Josh GottheimerD | Jun 11, 2025 | May 14, 2025 | Sell | $1,001 - $15,000 | +27.66% |
| Jefferson ShreveR | Jun 22, 2025 | May 12, 2025 | Sell | $15,001 - $50,000 | +20.97% |
| Marjorie Taylor GreeneR | May 6, 2025 | May 5, 2025 | Buy | $1,001 - $15,000 | +22.16% |
| Marjorie Taylor GreeneR | May 6, 2025 | May 5, 2025 | Buy | $1,001 - $15,000 | +22.16% |
| John BoozmanR | May 14, 2025 | Apr 16, 2025 | Sell | $1,001 - $15,000 | +19.75% |
| Jefferson ShreveR | Apr 11, 2025 | Mar 31, 2025 | Buy | $15,001 - $50,000 | +12.08% |
| Carol D. MillerR | Apr 11, 2025 | Mar 10, 2025 | Buy | $1,001 - $15,000 | +7.15% |
| Josh GottheimerD | Apr 10, 2025 | Mar 7, 2025 | Buy | $1,001 - $15,000 | +6.97% |